Abstract
The PI3-K family is one of the most intensely pursued classes of drug targets. This chapter reviews some of the chemical and structural features that determine the selectivity of PI3-K inhibitors, by focusing on a few key compounds that have been instrumental in guiding our understanding of how to design drugs against this family.
MeSH terms
-
Adenine / analogs & derivatives
-
Adenine / pharmacology
-
Androstadienes / pharmacology
-
Animals
-
Ataxia Telangiectasia Mutated Proteins
-
Cell Cycle Proteins / antagonists & inhibitors
-
Chromones / pharmacology
-
DNA-Activated Protein Kinase
-
DNA-Binding Proteins / antagonists & inhibitors
-
Humans
-
Morpholines / pharmacology
-
Neoplasms / drug therapy
-
Nuclear Proteins
-
Phosphoinositide-3 Kinase Inhibitors*
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Serine-Threonine Kinases / antagonists & inhibitors
-
Quinazolines / pharmacology
-
Tumor Suppressor Proteins / antagonists & inhibitors
-
Wortmannin
Substances
-
Androstadienes
-
Cell Cycle Proteins
-
Chromones
-
DNA-Binding Proteins
-
IC 87114
-
Morpholines
-
Nuclear Proteins
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Kinase Inhibitors
-
Quinazolines
-
Tumor Suppressor Proteins
-
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
-
ATM protein, human
-
Ataxia Telangiectasia Mutated Proteins
-
Atm protein, mouse
-
DNA-Activated Protein Kinase
-
Prkdc protein, mouse
-
Protein Serine-Threonine Kinases
-
Adenine
-
Wortmannin